{"id":53904,"date":"2026-01-13T14:19:19","date_gmt":"2026-01-13T06:19:19","guid":{"rendered":"https:\/\/flcube.com\/?p=53904"},"modified":"2026-01-13T14:19:19","modified_gmt":"2026-01-13T06:19:19","slug":"remegen-licenses-rc148-bispecific-to-abbvie-for-up-to-5-6-billion-in-milestones","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53904","title":{"rendered":"RemeGen Licenses RC148 Bispecific to AbbVie for Up to $5.6\u202fBillion in Milestones"},"content":{"rendered":"\n<p><strong>RemeGen Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688331:SHA\">SHA:\u202f688331<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/9995:HKG\">HKG:\u202f9995<\/a>) announced an <strong>exclusive licensing agreement<\/strong> with <strong>AbbVie Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/ABBV:NYSE\">NYSE:\u202fABBV<\/a>) for <strong>RC148<\/strong>, a novel <strong>PD\u20111\/VEGF bispecific antibody<\/strong>, granting AbbVie exclusive rights to develop, manufacture, and commercialize the asset in <strong>all regions outside Greater China<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-milestone\">Deal Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Parties<\/strong><\/td><td>RemeGen (SHA:\u202f688331, HKG:\u202f9995) &amp; AbbVie (NYSE:\u202fABBV)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>RC148 (PD\u20111\/VEGF bispecific antibody)<\/td><\/tr><tr><td><strong>Licensed Territory<\/strong><\/td><td>Worldwide excluding Greater China<\/td><\/tr><tr><td><strong>Rights<\/strong><\/td><td>Exclusive development, manufacturing, commercialization<\/td><\/tr><tr><td><strong>Indication Focus<\/strong><\/td><td>Advanced malignant solid tumors (monotherapy &amp; combinations)<\/td><\/tr><tr><td><strong>Agreement Effective<\/strong><\/td><td>Upon receipt of relevant regulatory approvals<\/td><\/tr><tr><td><strong>Strategic Rationale<\/strong><\/td><td>Expands AbbVie\u2019s oncology pipeline beyond hematology into solid tumors<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile\">Drug Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Novel <strong>PD\u20111\/VEGF bispecific antibody<\/strong> designed to simultaneously activate anti\u2011tumor immune responses while inhibiting tumor\u2011driven angiogenesis<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Dual targeting of <strong>PD\u20111 checkpoint<\/strong> and <strong>VEGF pathway<\/strong> within a single molecule, potentially offering synergistic efficacy and improved tumor microenvironment modulation<\/li>\n\n\n\n<li><strong>Development Stage:<\/strong> Ongoing clinical studies in China evaluating RC148 both as <strong>monotherapy<\/strong> and in <strong>combination regimens<\/strong> for various advanced solid tumors (trial details undisclosed)<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> Single\u2011agent dual\u2011blockade may reduce need for combination chemotherapy and manage resistance vs. separate PD\u20111 + VEGF inhibitor combinations<\/li>\n\n\n\n<li><strong>Intellectual Property:<\/strong> Global patent family filed; RemeGen retains full rights in Greater China<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-terms\">Financial Terms<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Amount\/Terms<\/th><\/tr><\/thead><tbody><tr><td><strong>Upfront Payment<\/strong><\/td><td>USD <strong>650\u202fmillion<\/strong> (upon regulatory approval of agreement)<\/td><\/tr><tr><td><strong>Development Milestones<\/strong><\/td><td>Up to USD <strong>2.1\u202fbillion<\/strong> (Phase\u202fII\/III initiation, data readouts)<\/td><\/tr><tr><td><strong>Regulatory Milestones<\/strong><\/td><td>Up to USD <strong>1.4\u202fbillion<\/strong> (BLA\/MAA approvals in US\/EU\/Japan)<\/td><\/tr><tr><td><strong>Commercial Milestones<\/strong><\/td><td>Up to USD <strong>1.45\u202fbillion<\/strong> (annual sales thresholds)<\/td><\/tr><tr><td><strong>Total Deal Value<\/strong><\/td><td><strong>Up to USD 5.6\u202fbillion<\/strong><\/td><\/tr><tr><td><strong>Royalties<\/strong><\/td><td><strong>Tiered double\u2011digit royalties<\/strong> on net sales outside Greater China<\/td><\/tr><tr><td><strong>RemeGen Retains<\/strong><\/td><td>Full rights to RC148 in Greater China, plus manufacturing technology transfer fees<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-outlook\">Market Opportunity &amp; Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>2026E<\/th><th>2027E<\/th><th>2028E<\/th><\/tr><\/thead><tbody><tr><td><strong>Global PD\u20111\/VEGF Bispecific Market<\/strong><\/td><td>$0.8\u202fbillion<\/td><td>$2.1\u202fbillion<\/td><td>$4.5\u202fbillion<\/td><\/tr><tr><td><strong>Solid Tumor Indications (RC148\u2011eligible)<\/strong><\/td><td>1.2\u202fmillion<\/td><td>1.25\u202fmillion<\/td><td>1.3\u202fmillion<\/td><\/tr><tr><td><strong>AbbVie Peak Market Share Target<\/strong><\/td><td>\u2013<\/td><td>8\u202f%<\/td><td>15\u202f%<\/td><\/tr><tr><td><strong>Peak Annual Sales Potential (ex\u2011China)<\/strong><\/td><td>\u2013<\/td><td>\u2013<\/td><td>$2.4\u202fbillion (2033E)<\/td><\/tr><tr><td><strong>RemeGen Royalty Forecast<\/strong><\/td><td>\u2013<\/td><td>$48\u202fmillion<\/td><td>$192\u202fmillion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Competitive Landscape:<\/strong><\/li>\n\n\n\n<li><strong>Akeso\u2019s ivonescimab<\/strong> (PD\u20111\/VEGF bispecific) approved in China (2024) for NSCLC; pursuing global trials<\/li>\n\n\n\n<li><strong>NMPA\u2019s cadonilimab<\/strong> (PD\u20111\/CTLA\u20114) and <strong>Summit\/Tivdak<\/strong> combos in development<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> RC148\u2019s <strong>human IgG1 scaffold<\/strong> and <strong>optimized Fc\u03b3R binding<\/strong> may offer <strong>superior ADCC<\/strong> and <strong>reduced immune\u2011related adverse events<\/strong> vs. competitors<\/li>\n\n\n\n<li><strong>Strategic Value for AbbVie:<\/strong><\/li>\n\n\n\n<li>Strengthens oncology portfolio post\u2011Imbruvica erosion; complements <strong>AbbVie\u2019s ADC platform<\/strong> (eGen\u20117829) and <strong>emdatritinib<\/strong> (FGFR2 inhibitor)<\/li>\n\n\n\n<li>Access to China\u2011generated clinical data accelerates global development timeline by <strong>12\u201118\u202fmonths<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning\">Strategic Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>For RemeGen:<\/strong><\/li>\n\n\n\n<li><strong>Largest upfront payment<\/strong> for a Chinese biotech asset since 2023, validating its <strong>bispecific platform<\/strong><\/li>\n\n\n\n<li>Capital infusion funds <strong>RC148 China trials<\/strong> and <strong>next\u2011generation pipeline<\/strong> (CLDN18.2 ADC, TROP2 ADC)<\/li>\n\n\n\n<li>Retains <strong>Greater China rights<\/strong> in high\u2011growth domestic market (estimated \u00a515\u202fbillion peak sales)<\/li>\n\n\n\n<li><strong>For AbbVie:<\/strong><\/li>\n\n\n\n<li>Expands beyond hematology into <strong>solid tumors<\/strong> with a potentially best\u2011in\u2011class bispecific<\/li>\n\n\n\n<li>Leverages <strong>global oncology commercial footprint<\/strong> (4,000+ field force) for rapid market penetration<\/li>\n\n\n\n<li>Supports <strong>&#8220;pharma\u2011diversity&#8221;<\/strong> strategy amid Humira biosimilar competition<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding RC148 development milestones, potential regulatory approvals, and projected royalty streams. Actual results may differ due to competitive dynamics, clinical trial outcomes, and AbbVie\u2019s strategic prioritization.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2026011201186_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026011201186_c.\"><\/object><a id=\"wp-block-file--media-a0543156-bfa2-4b28-929c-6b12368b6f0c\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2026011201186_c.pdf\">2026011201186_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2026011201186_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-a0543156-bfa2-4b28-929c-6b12368b6f0c\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>RemeGen Co., Ltd. (SHA:\u202f688331, HKG:\u202f9995) announced an exclusive licensing agreement with AbbVie Inc. (NYSE:\u202fABBV) for&#8230;<\/p>\n","protected":false},"author":1,"featured_media":53907,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[234,1155,28,853,18,375],"class_list":["post-53904","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-abbvie","tag-hkg-9995","tag-multi-specific-antibodies","tag-nyse-abbv","tag-pd-1-l1","tag-remegen"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>RemeGen Licenses RC148 Bispecific to AbbVie for Up to $5.6\u202fBillion in Milestones - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"RemeGen Co., Ltd. (SHA:\u202f688331, HKG:\u202f9995) announced an exclusive licensing agreement with AbbVie Inc. (NYSE:\u202fABBV) for RC148, a novel PD\u20111\/VEGF bispecific antibody, granting AbbVie exclusive rights to develop, manufacture, and commercialize the asset in all regions outside Greater China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53904\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"RemeGen Licenses RC148 Bispecific to AbbVie for Up to $5.6\u202fBillion in Milestones\" \/>\n<meta property=\"og:description\" content=\"RemeGen Co., Ltd. (SHA:\u202f688331, HKG:\u202f9995) announced an exclusive licensing agreement with AbbVie Inc. (NYSE:\u202fABBV) for RC148, a novel PD\u20111\/VEGF bispecific antibody, granting AbbVie exclusive rights to develop, manufacture, and commercialize the asset in all regions outside Greater China.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53904\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-13T06:19:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1306.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53904#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53904\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"RemeGen Licenses RC148 Bispecific to AbbVie for Up to $5.6\u202fBillion in Milestones\",\"datePublished\":\"2026-01-13T06:19:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53904\"},\"wordCount\":534,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53904#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/1306.webp\",\"keywords\":[\"AbbVie\",\"HKG: 9995\",\"Multi-specific antibodies\",\"NYSE: ABBV\",\"PD-1\\\/L1\",\"RemeGen\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53904#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53904\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53904\",\"name\":\"RemeGen Licenses RC148 Bispecific to AbbVie for Up to $5.6\u202fBillion in Milestones - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53904#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53904#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/1306.webp\",\"datePublished\":\"2026-01-13T06:19:19+00:00\",\"description\":\"RemeGen Co., Ltd. (SHA:\u202f688331, HKG:\u202f9995) announced an exclusive licensing agreement with AbbVie Inc. (NYSE:\u202fABBV) for RC148, a novel PD\u20111\\\/VEGF bispecific antibody, granting AbbVie exclusive rights to develop, manufacture, and commercialize the asset in all regions outside Greater China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53904#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53904\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53904#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/1306.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/1306.webp\",\"width\":1080,\"height\":608,\"caption\":\"RemeGen Licenses RC148 Bispecific to AbbVie for Up to $5.6\u202fBillion in Milestones\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53904#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"RemeGen Licenses RC148 Bispecific to AbbVie for Up to $5.6\u202fBillion in Milestones\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"RemeGen Licenses RC148 Bispecific to AbbVie for Up to $5.6\u202fBillion in Milestones - Insight, China&#039;s Pharmaceutical Industry","description":"RemeGen Co., Ltd. (SHA:\u202f688331, HKG:\u202f9995) announced an exclusive licensing agreement with AbbVie Inc. (NYSE:\u202fABBV) for RC148, a novel PD\u20111\/VEGF bispecific antibody, granting AbbVie exclusive rights to develop, manufacture, and commercialize the asset in all regions outside Greater China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53904","og_locale":"en_US","og_type":"article","og_title":"RemeGen Licenses RC148 Bispecific to AbbVie for Up to $5.6\u202fBillion in Milestones","og_description":"RemeGen Co., Ltd. (SHA:\u202f688331, HKG:\u202f9995) announced an exclusive licensing agreement with AbbVie Inc. (NYSE:\u202fABBV) for RC148, a novel PD\u20111\/VEGF bispecific antibody, granting AbbVie exclusive rights to develop, manufacture, and commercialize the asset in all regions outside Greater China.","og_url":"https:\/\/flcube.com\/?p=53904","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-13T06:19:19+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1306.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53904#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53904"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"RemeGen Licenses RC148 Bispecific to AbbVie for Up to $5.6\u202fBillion in Milestones","datePublished":"2026-01-13T06:19:19+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53904"},"wordCount":534,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=53904#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1306.webp","keywords":["AbbVie","HKG: 9995","Multi-specific antibodies","NYSE: ABBV","PD-1\/L1","RemeGen"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53904#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53904","url":"https:\/\/flcube.com\/?p=53904","name":"RemeGen Licenses RC148 Bispecific to AbbVie for Up to $5.6\u202fBillion in Milestones - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=53904#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=53904#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1306.webp","datePublished":"2026-01-13T06:19:19+00:00","description":"RemeGen Co., Ltd. (SHA:\u202f688331, HKG:\u202f9995) announced an exclusive licensing agreement with AbbVie Inc. (NYSE:\u202fABBV) for RC148, a novel PD\u20111\/VEGF bispecific antibody, granting AbbVie exclusive rights to develop, manufacture, and commercialize the asset in all regions outside Greater China.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53904#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53904"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=53904#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1306.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1306.webp","width":1080,"height":608,"caption":"RemeGen Licenses RC148 Bispecific to AbbVie for Up to $5.6\u202fBillion in Milestones"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53904#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"RemeGen Licenses RC148 Bispecific to AbbVie for Up to $5.6\u202fBillion in Milestones"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1306.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53904","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53904"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53904\/revisions"}],"predecessor-version":[{"id":53908,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53904\/revisions\/53908"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/53907"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53904"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53904"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53904"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}